NeuroMetrix, Inc. (NURO)
NASDAQ: NURO · Real-Time Price · USD
4.420
+0.010 (0.23%)
Apr 2, 2025, 4:00 PM EDT - Market closed
NeuroMetrix Revenue
In the year 2024, NeuroMetrix had annual revenue of $3.03M, down -48.61%. NeuroMetrix had revenue of $582.82K in the quarter ending December 31, 2024, a decrease of -55.77%.
Revenue (ttm)
$3.03M
Revenue Growth
-48.61%
P/S Ratio
2.86
Revenue / Employee
$116,648
Employees
26
Market Cap
9.03M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.03M | -2.87M | -48.61% |
Dec 31, 2023 | 5.90M | -2.35M | -28.52% |
Dec 31, 2022 | 8.26M | 2.58K | 0.03% |
Dec 31, 2021 | 8.25M | 875.52K | 11.87% |
Dec 31, 2020 | 7.38M | -1.89M | -20.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
NURO News
- 3 months ago - NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO - Business Wire
- 3 months ago - NeuroMetrix to be Acquired by electroCore - GlobeNewsWire
- 8 months ago - NeuroMetrix Reiterates its Review of Strategic Alternatives - GlobeNewsWire
- 8 months ago - NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 8 months ago - NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call - GlobeNewsWire
- 11 months ago - NeuroMetrix Reports Q1 2024 Business Highlights - GlobeNewsWire
- 1 year ago - NeuroMetrix Announces Steps Taken to Enhance Shareholder Value - GlobeNewsWire
- 1 year ago - NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy - GlobeNewsWire